Coronavirus News Roundup: Johnson & Johnson Submits EUA for COVID-19 Vaccine Candidate, Poll Finds Americans Dissatisfied With Vaccine Rollout


Here's the roundup of the latest coronavirus-related news.

coronavirus news roundup

The coronavirus disease 2019 (COVID-19) vaccination effort is well underway in the US, with over 46.4 million administered doses and 11 million Americans fully vaccinated against the virus as of press time. This week, Johnson & Johnson submitted an emergency use authorization (EUA) for its COVID-19 investigational vaccine, and a new Gallup poll reported many Americans being dissatisfied with the vaccine rollout.

Here’s a roundup of the latest coronavirus-related news:

Gallup Poll: Many Americans Dissatisfied With COVID-19 Vaccine Rollout

Nearly two-thirds of Americans are not satisfied with the rollout of the COVID-19 vaccine in the United States, according to results of a new Gallup poll.

Read more

FDA Authorizes Bamlanivimab-Etesevimab Combination Treatment for COVID-19

Officials with the FDA have issued an EUA to Eli Lilly for the combination treatment of bamlanivimab and etesevimab for mild-to-moderate COVID-19 in adult and pediatric patients at high risk for severe infection.

Read more

AHA Urges Americans With Heart Disease to Receive COVID-19 Vaccines

The American Heart Association (AHA) is urging all Americans—but particularly those with heart conditions or who are at risk for cardiovascular disease—to receive the COVID-19 vaccine.

Read more

Johnson & Johnson Submits EUA for COVID-19 Vaccine Candidate

Johnson & Johnson has submitted an EUA to the FDA for its single-dose vaccine candidate for COVID-19.

Read more

Pharmacy Students Administer COVID-19 Vaccines

Drug Topics interviewed Karen Mackinnon and Sara Revolinski from the Medical College of Wisconsin School of Pharmacy about how their pharmacy students have been rising to meet the demand of the pandemic by administering COVID-19 vaccines.

Watch the interview.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.